nodes	percent_of_prediction	percent_of_DWPC	metapath
Propofol—CYP2B6—Thiotepa—urinary bladder cancer	0.0899	0.177	CbGbCtD
Propofol—UGT1A1—Etoposide—urinary bladder cancer	0.063	0.124	CbGbCtD
Propofol—CYP1B1—Doxorubicin—urinary bladder cancer	0.0497	0.0981	CbGbCtD
Propofol—CYP2A6—Fluorouracil—urinary bladder cancer	0.0449	0.0885	CbGbCtD
Propofol—ALB—Fluorouracil—urinary bladder cancer	0.0286	0.0565	CbGbCtD
Propofol—CYP3A4—Thiotepa—urinary bladder cancer	0.0276	0.0545	CbGbCtD
Propofol—CYP2B6—Cisplatin—urinary bladder cancer	0.0248	0.0489	CbGbCtD
Propofol—CYP2E1—Etoposide—urinary bladder cancer	0.0247	0.0488	CbGbCtD
Propofol—CYP2C8—Fluorouracil—urinary bladder cancer	0.0221	0.0436	CbGbCtD
Propofol—CYP2C8—Etoposide—urinary bladder cancer	0.0185	0.0364	CbGbCtD
Propofol—CYP1A2—Fluorouracil—urinary bladder cancer	0.0171	0.0338	CbGbCtD
Propofol—CYP2B6—Doxorubicin—urinary bladder cancer	0.0166	0.0328	CbGbCtD
Propofol—ALB—Methotrexate—urinary bladder cancer	0.0158	0.0311	CbGbCtD
Propofol—CYP2C9—Fluorouracil—urinary bladder cancer	0.0154	0.0304	CbGbCtD
Propofol—CYP1A2—Etoposide—urinary bladder cancer	0.0143	0.0282	CbGbCtD
Propofol—CYP2C9—Cisplatin—urinary bladder cancer	0.0131	0.0259	CbGbCtD
Propofol—CYP2D6—Doxorubicin—urinary bladder cancer	0.00803	0.0158	CbGbCtD
Propofol—CYP3A4—Etoposide—urinary bladder cancer	0.00749	0.0148	CbGbCtD
Propofol—UGT1A1—urine—urinary bladder cancer	0.00662	0.0715	CbGeAlD
Propofol—UGT1A6—prostate gland—urinary bladder cancer	0.00642	0.0694	CbGeAlD
Propofol—CYP3A4—Doxorubicin—urinary bladder cancer	0.00511	0.0101	CbGbCtD
Propofol—FAAH—prostate gland—urinary bladder cancer	0.00397	0.0429	CbGeAlD
Propofol—UGT1A8—renal system—urinary bladder cancer	0.00372	0.0402	CbGeAlD
Propofol—CYP2C19—urine—urinary bladder cancer	0.00359	0.0388	CbGeAlD
Propofol—FAAH—seminal vesicle—urinary bladder cancer	0.00336	0.0362	CbGeAlD
Propofol—CYP1A2—urine—urinary bladder cancer	0.00293	0.0317	CbGeAlD
Propofol—CYP2C9—urine—urinary bladder cancer	0.00278	0.0301	CbGeAlD
Propofol—FAAH—renal system—urinary bladder cancer	0.00271	0.0292	CbGeAlD
Propofol—FAAH—urethra—urinary bladder cancer	0.00266	0.0287	CbGeAlD
Propofol—CYP2E1—urine—urinary bladder cancer	0.00264	0.0285	CbGeAlD
Propofol—SCN4A—prostate gland—urinary bladder cancer	0.00258	0.0278	CbGeAlD
Propofol—UGT1A1—prostate gland—urinary bladder cancer	0.00238	0.0257	CbGeAlD
Propofol—UGT1A9—renal system—urinary bladder cancer	0.00236	0.0255	CbGeAlD
Propofol—FAAH—female reproductive system—urinary bladder cancer	0.00217	0.0234	CbGeAlD
Propofol—CYP3A4—urine—urinary bladder cancer	0.00212	0.0229	CbGeAlD
Propofol—CYP2D6—urine—urinary bladder cancer	0.00209	0.0226	CbGeAlD
Propofol—CYP2A6—prostate gland—urinary bladder cancer	0.002	0.0216	CbGeAlD
Propofol—FAAH—vagina—urinary bladder cancer	0.00196	0.0212	CbGeAlD
Propofol—SCN4A—renal system—urinary bladder cancer	0.00176	0.019	CbGeAlD
Propofol—CYP2A6—seminal vesicle—urinary bladder cancer	0.0017	0.0183	CbGeAlD
Propofol—UGT1A1—renal system—urinary bladder cancer	0.00162	0.0175	CbGeAlD
Propofol—CYP2C18—vagina—urinary bladder cancer	0.0015	0.0162	CbGeAlD
Propofol—GABRB3—prostate gland—urinary bladder cancer	0.00149	0.0161	CbGeAlD
Propofol—CYP1B1—prostate gland—urinary bladder cancer	0.00147	0.0159	CbGeAlD
Propofol—FAAH—lymph node—urinary bladder cancer	0.00127	0.0137	CbGeAlD
Propofol—SCN2A—vagina—urinary bladder cancer	0.00113	0.0122	CbGeAlD
Propofol—CYP1B1—smooth muscle tissue—urinary bladder cancer	0.00104	0.0112	CbGeAlD
Propofol—CYP1B1—renal system—urinary bladder cancer	0.001	0.0108	CbGeAlD
Propofol—CYP2A6—vagina—urinary bladder cancer	0.000989	0.0107	CbGeAlD
Propofol—CYP2E1—prostate gland—urinary bladder cancer	0.000947	0.0102	CbGeAlD
Propofol—GABRA2—vagina—urinary bladder cancer	0.000874	0.00944	CbGeAlD
Propofol—GABRB3—female reproductive system—urinary bladder cancer	0.000813	0.00877	CbGeAlD
Propofol—CYP1B1—female reproductive system—urinary bladder cancer	0.000802	0.00866	CbGeAlD
Propofol—CYP2E1—seminal vesicle—urinary bladder cancer	0.000801	0.00865	CbGeAlD
Propofol—CYP2C8—renal system—urinary bladder cancer	0.000767	0.00828	CbGeAlD
Propofol—CYP1A1—epithelium—urinary bladder cancer	0.000763	0.00824	CbGeAlD
Propofol—CYP1A2—renal system—urinary bladder cancer	0.000718	0.00775	CbGeAlD
Propofol—CYP1A1—renal system—urinary bladder cancer	0.000708	0.00764	CbGeAlD
Propofol—CYP1A1—urethra—urinary bladder cancer	0.000695	0.00751	CbGeAlD
Propofol—CYP2B6—renal system—urinary bladder cancer	0.000688	0.00743	CbGeAlD
Propofol—CYP2E1—renal system—urinary bladder cancer	0.000645	0.00697	CbGeAlD
Propofol—CYP2C19—vagina—urinary bladder cancer	0.000636	0.00687	CbGeAlD
Propofol—CYP2E1—urethra—urinary bladder cancer	0.000634	0.00685	CbGeAlD
Propofol—CYP2C8—female reproductive system—urinary bladder cancer	0.000614	0.00663	CbGeAlD
Propofol—CYP1A1—female reproductive system—urinary bladder cancer	0.000567	0.00612	CbGeAlD
Propofol—GABRA2—lymph node—urinary bladder cancer	0.000566	0.00611	CbGeAlD
Propofol—CYP2C8—vagina—urinary bladder cancer	0.000555	0.006	CbGeAlD
Propofol—CYP2B6—female reproductive system—urinary bladder cancer	0.000551	0.00595	CbGeAlD
Propofol—CYP2C9—female reproductive system—urinary bladder cancer	0.000545	0.00589	CbGeAlD
Propofol—CYP3A4—renal system—urinary bladder cancer	0.000519	0.00561	CbGeAlD
Propofol—CYP2E1—female reproductive system—urinary bladder cancer	0.000517	0.00558	CbGeAlD
Propofol—CYP1A1—vagina—urinary bladder cancer	0.000513	0.00554	CbGeAlD
Propofol—ALB—lymph node—urinary bladder cancer	0.000511	0.00552	CbGeAlD
Propofol—CYP2D6—renal system—urinary bladder cancer	0.000511	0.00552	CbGeAlD
Propofol—CYP2B6—vagina—urinary bladder cancer	0.000498	0.00538	CbGeAlD
Propofol—CYP1B1—lymph node—urinary bladder cancer	0.000469	0.00507	CbGeAlD
Propofol—CYP3A4—female reproductive system—urinary bladder cancer	0.000416	0.00449	CbGeAlD
Propofol—CYP2D6—female reproductive system—urinary bladder cancer	0.000409	0.00442	CbGeAlD
Propofol—CYP1A1—lymph node—urinary bladder cancer	0.000332	0.00358	CbGeAlD
Propofol—Abdominal pain—Thiotepa—urinary bladder cancer	0.000234	0.00125	CcSEcCtD
Propofol—Body temperature increased—Thiotepa—urinary bladder cancer	0.000234	0.00125	CcSEcCtD
Propofol—Hypotension—Gemcitabine—urinary bladder cancer	0.000233	0.00124	CcSEcCtD
Propofol—Oedema—Cisplatin—urinary bladder cancer	0.000232	0.00124	CcSEcCtD
Propofol—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000232	0.00124	CcSEcCtD
Propofol—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000232	0.00124	CcSEcCtD
Propofol—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000231	0.00123	CcSEcCtD
Propofol—Cardiac failure—Doxorubicin—urinary bladder cancer	0.00023	0.00123	CcSEcCtD
Propofol—Mood swings—Epirubicin—urinary bladder cancer	0.00023	0.00122	CcSEcCtD
Propofol—Loss of consciousness—Etoposide—urinary bladder cancer	0.000229	0.00122	CcSEcCtD
Propofol—Hypotension—Fluorouracil—urinary bladder cancer	0.000229	0.00122	CcSEcCtD
Propofol—Cough—Etoposide—urinary bladder cancer	0.000227	0.00121	CcSEcCtD
Propofol—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000227	0.00121	CcSEcCtD
Propofol—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000227	0.00121	CcSEcCtD
Propofol—Tachycardia—Cisplatin—urinary bladder cancer	0.000226	0.00121	CcSEcCtD
Propofol—Convulsion—Etoposide—urinary bladder cancer	0.000226	0.0012	CcSEcCtD
Propofol—Dehydration—Epirubicin—urinary bladder cancer	0.000225	0.0012	CcSEcCtD
Propofol—Insomnia—Gemcitabine—urinary bladder cancer	0.000225	0.0012	CcSEcCtD
Propofol—Hypertension—Etoposide—urinary bladder cancer	0.000225	0.0012	CcSEcCtD
Propofol—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000224	0.0012	CcSEcCtD
Propofol—Diplopia—Doxorubicin—urinary bladder cancer	0.000224	0.0012	CcSEcCtD
Propofol—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000224	0.0012	CcSEcCtD
Propofol—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000224	0.00119	CcSEcCtD
Propofol—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000223	0.00119	CcSEcCtD
Propofol—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000222	0.00118	CcSEcCtD
Propofol—Chest pain—Etoposide—urinary bladder cancer	0.000222	0.00118	CcSEcCtD
Propofol—Insomnia—Fluorouracil—urinary bladder cancer	0.000221	0.00118	CcSEcCtD
Propofol—Somnolence—Gemcitabine—urinary bladder cancer	0.000221	0.00118	CcSEcCtD
Propofol—Affect lability—Doxorubicin—urinary bladder cancer	0.000221	0.00118	CcSEcCtD
Propofol—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00022	0.00117	CcSEcCtD
Propofol—Pancreatitis—Methotrexate—urinary bladder cancer	0.00022	0.00117	CcSEcCtD
Propofol—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000218	0.00116	CcSEcCtD
Propofol—Somnolence—Fluorouracil—urinary bladder cancer	0.000218	0.00116	CcSEcCtD
Propofol—Hypotension—Cisplatin—urinary bladder cancer	0.000217	0.00116	CcSEcCtD
Propofol—Fatigue—Gemcitabine—urinary bladder cancer	0.000215	0.00114	CcSEcCtD
Propofol—Confusional state—Etoposide—urinary bladder cancer	0.000214	0.00114	CcSEcCtD
Propofol—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000213	0.00114	CcSEcCtD
Propofol—Pain—Gemcitabine—urinary bladder cancer	0.000213	0.00113	CcSEcCtD
Propofol—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000213	0.00113	CcSEcCtD
Propofol—Mood swings—Doxorubicin—urinary bladder cancer	0.000213	0.00113	CcSEcCtD
Propofol—Asthenia—Thiotepa—urinary bladder cancer	0.000212	0.00113	CcSEcCtD
Propofol—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000211	0.00113	CcSEcCtD
Propofol—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.00021	0.00112	CcSEcCtD
Propofol—Pruritus—Thiotepa—urinary bladder cancer	0.000209	0.00112	CcSEcCtD
Propofol—Pain—Fluorouracil—urinary bladder cancer	0.000209	0.00112	CcSEcCtD
Propofol—Dehydration—Doxorubicin—urinary bladder cancer	0.000209	0.00111	CcSEcCtD
Propofol—Paraesthesia—Cisplatin—urinary bladder cancer	0.000208	0.00111	CcSEcCtD
Propofol—Tachycardia—Etoposide—urinary bladder cancer	0.000207	0.00111	CcSEcCtD
Propofol—Dyspnoea—Cisplatin—urinary bladder cancer	0.000207	0.0011	CcSEcCtD
Propofol—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000206	0.0011	CcSEcCtD
Propofol—Pancreatitis—Epirubicin—urinary bladder cancer	0.000205	0.0011	CcSEcCtD
Propofol—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000205	0.00109	CcSEcCtD
Propofol—Diarrhoea—Thiotepa—urinary bladder cancer	0.000202	0.00108	CcSEcCtD
Propofol—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000202	0.00108	CcSEcCtD
Propofol—Depression—Methotrexate—urinary bladder cancer	0.000199	0.00106	CcSEcCtD
Propofol—Hypotension—Etoposide—urinary bladder cancer	0.000199	0.00106	CcSEcCtD
Propofol—Pain—Cisplatin—urinary bladder cancer	0.000198	0.00106	CcSEcCtD
Propofol—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000197	0.00105	CcSEcCtD
Propofol—Renal failure—Methotrexate—urinary bladder cancer	0.000196	0.00105	CcSEcCtD
Propofol—Dizziness—Thiotepa—urinary bladder cancer	0.000196	0.00104	CcSEcCtD
Propofol—Urticaria—Fluorouracil—urinary bladder cancer	0.000194	0.00104	CcSEcCtD
Propofol—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000193	0.00103	CcSEcCtD
Propofol—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000191	0.00102	CcSEcCtD
Propofol—Paraesthesia—Etoposide—urinary bladder cancer	0.000191	0.00102	CcSEcCtD
Propofol—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00019	0.00101	CcSEcCtD
Propofol—Dyspnoea—Etoposide—urinary bladder cancer	0.00019	0.00101	CcSEcCtD
Propofol—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000189	0.00101	CcSEcCtD
Propofol—Somnolence—Etoposide—urinary bladder cancer	0.000189	0.00101	CcSEcCtD
Propofol—Vomiting—Thiotepa—urinary bladder cancer	0.000188	0.001	CcSEcCtD
Propofol—Rash—Thiotepa—urinary bladder cancer	0.000187	0.000995	CcSEcCtD
Propofol—Dermatitis—Thiotepa—urinary bladder cancer	0.000186	0.000994	CcSEcCtD
Propofol—Headache—Thiotepa—urinary bladder cancer	0.000185	0.000988	CcSEcCtD
Propofol—Renal failure—Epirubicin—urinary bladder cancer	0.000184	0.000979	CcSEcCtD
Propofol—Body temperature increased—Cisplatin—urinary bladder cancer	0.000183	0.000978	CcSEcCtD
Propofol—Fatigue—Etoposide—urinary bladder cancer	0.000183	0.000977	CcSEcCtD
Propofol—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000183	0.000976	CcSEcCtD
Propofol—Pain—Etoposide—urinary bladder cancer	0.000182	0.000969	CcSEcCtD
Propofol—Haemoglobin—Methotrexate—urinary bladder cancer	0.00018	0.00096	CcSEcCtD
Propofol—Haemorrhage—Methotrexate—urinary bladder cancer	0.000179	0.000955	CcSEcCtD
Propofol—Asthenia—Gemcitabine—urinary bladder cancer	0.000179	0.000952	CcSEcCtD
Propofol—Pharyngitis—Methotrexate—urinary bladder cancer	0.000178	0.000948	CcSEcCtD
Propofol—Pruritus—Gemcitabine—urinary bladder cancer	0.000176	0.000939	CcSEcCtD
Propofol—Nausea—Thiotepa—urinary bladder cancer	0.000176	0.000937	CcSEcCtD
Propofol—Feeling abnormal—Etoposide—urinary bladder cancer	0.000175	0.000934	CcSEcCtD
Propofol—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000175	0.000932	CcSEcCtD
Propofol—Pruritus—Fluorouracil—urinary bladder cancer	0.000173	0.000923	CcSEcCtD
Propofol—Visual impairment—Methotrexate—urinary bladder cancer	0.000173	0.000921	CcSEcCtD
Propofol—Bradycardia—Epirubicin—urinary bladder cancer	0.000171	0.00091	CcSEcCtD
Propofol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00017	0.000908	CcSEcCtD
Propofol—Renal failure—Doxorubicin—urinary bladder cancer	0.00017	0.000906	CcSEcCtD
Propofol—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000169	0.000903	CcSEcCtD
Propofol—Urticaria—Etoposide—urinary bladder cancer	0.000169	0.0009	CcSEcCtD
Propofol—Haemoglobin—Epirubicin—urinary bladder cancer	0.000169	0.000899	CcSEcCtD
Propofol—Abdominal pain—Etoposide—urinary bladder cancer	0.000168	0.000896	CcSEcCtD
Propofol—Body temperature increased—Etoposide—urinary bladder cancer	0.000168	0.000896	CcSEcCtD
Propofol—Haemorrhage—Epirubicin—urinary bladder cancer	0.000168	0.000894	CcSEcCtD
Propofol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000167	0.000893	CcSEcCtD
Propofol—Tinnitus—Methotrexate—urinary bladder cancer	0.000167	0.000891	CcSEcCtD
Propofol—Asthenia—Cisplatin—urinary bladder cancer	0.000166	0.000888	CcSEcCtD
Propofol—Pharyngitis—Epirubicin—urinary bladder cancer	0.000166	0.000887	CcSEcCtD
Propofol—Dizziness—Fluorouracil—urinary bladder cancer	0.000162	0.000863	CcSEcCtD
Propofol—Visual impairment—Epirubicin—urinary bladder cancer	0.000162	0.000862	CcSEcCtD
Propofol—Chills—Methotrexate—urinary bladder cancer	0.000161	0.000857	CcSEcCtD
Propofol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000159	0.000846	CcSEcCtD
Propofol—Vomiting—Gemcitabine—urinary bladder cancer	0.000158	0.000844	CcSEcCtD
Propofol—Bradycardia—Doxorubicin—urinary bladder cancer	0.000158	0.000842	CcSEcCtD
Propofol—Rash—Gemcitabine—urinary bladder cancer	0.000157	0.000837	CcSEcCtD
Propofol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000157	0.000836	CcSEcCtD
Propofol—Tinnitus—Epirubicin—urinary bladder cancer	0.000156	0.000834	CcSEcCtD
Propofol—Erythema—Methotrexate—urinary bladder cancer	0.000156	0.000832	CcSEcCtD
Propofol—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000156	0.000832	CcSEcCtD
Propofol—Headache—Gemcitabine—urinary bladder cancer	0.000156	0.000831	CcSEcCtD
Propofol—Flushing—Epirubicin—urinary bladder cancer	0.000156	0.00083	CcSEcCtD
Propofol—Vomiting—Fluorouracil—urinary bladder cancer	0.000156	0.00083	CcSEcCtD
Propofol—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000155	0.000827	CcSEcCtD
Propofol—Rash—Fluorouracil—urinary bladder cancer	0.000154	0.000823	CcSEcCtD
Propofol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000154	0.000822	CcSEcCtD
Propofol—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000154	0.000821	CcSEcCtD
Propofol—Headache—Fluorouracil—urinary bladder cancer	0.000153	0.000817	CcSEcCtD
Propofol—Dysgeusia—Methotrexate—urinary bladder cancer	0.000153	0.000814	CcSEcCtD
Propofol—Asthenia—Etoposide—urinary bladder cancer	0.000153	0.000813	CcSEcCtD
Propofol—Chills—Epirubicin—urinary bladder cancer	0.00015	0.000802	CcSEcCtD
Propofol—Pruritus—Etoposide—urinary bladder cancer	0.00015	0.000802	CcSEcCtD
Propofol—Arrhythmia—Epirubicin—urinary bladder cancer	0.00015	0.000799	CcSEcCtD
Propofol—Visual impairment—Doxorubicin—urinary bladder cancer	0.00015	0.000797	CcSEcCtD
Propofol—Nausea—Gemcitabine—urinary bladder cancer	0.000148	0.000788	CcSEcCtD
Propofol—Vomiting—Cisplatin—urinary bladder cancer	0.000148	0.000786	CcSEcCtD
Propofol—Rash—Cisplatin—urinary bladder cancer	0.000146	0.00078	CcSEcCtD
Propofol—Dermatitis—Cisplatin—urinary bladder cancer	0.000146	0.000779	CcSEcCtD
Propofol—Erythema—Epirubicin—urinary bladder cancer	0.000146	0.000778	CcSEcCtD
Propofol—Diarrhoea—Etoposide—urinary bladder cancer	0.000145	0.000775	CcSEcCtD
Propofol—Nausea—Fluorouracil—urinary bladder cancer	0.000145	0.000775	CcSEcCtD
Propofol—Tinnitus—Doxorubicin—urinary bladder cancer	0.000145	0.000771	CcSEcCtD
Propofol—Flushing—Doxorubicin—urinary bladder cancer	0.000144	0.000768	CcSEcCtD
Propofol—Dysgeusia—Epirubicin—urinary bladder cancer	0.000143	0.000762	CcSEcCtD
Propofol—Dizziness—Etoposide—urinary bladder cancer	0.000141	0.000749	CcSEcCtD
Propofol—Muscle spasms—Epirubicin—urinary bladder cancer	0.00014	0.000748	CcSEcCtD
Propofol—Chills—Doxorubicin—urinary bladder cancer	0.000139	0.000742	CcSEcCtD
Propofol—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000139	0.000739	CcSEcCtD
Propofol—Nausea—Cisplatin—urinary bladder cancer	0.000138	0.000735	CcSEcCtD
Propofol—Cough—Methotrexate—urinary bladder cancer	0.000136	0.000726	CcSEcCtD
Propofol—Convulsion—Methotrexate—urinary bladder cancer	0.000135	0.000721	CcSEcCtD
Propofol—Vomiting—Etoposide—urinary bladder cancer	0.000135	0.000721	CcSEcCtD
Propofol—Erythema—Doxorubicin—urinary bladder cancer	0.000135	0.00072	CcSEcCtD
Propofol—Agitation—Epirubicin—urinary bladder cancer	0.000134	0.000715	CcSEcCtD
Propofol—Rash—Etoposide—urinary bladder cancer	0.000134	0.000715	CcSEcCtD
Propofol—Dermatitis—Etoposide—urinary bladder cancer	0.000134	0.000714	CcSEcCtD
Propofol—Headache—Etoposide—urinary bladder cancer	0.000133	0.00071	CcSEcCtD
Propofol—Myalgia—Methotrexate—urinary bladder cancer	0.000133	0.000708	CcSEcCtD
Propofol—Chest pain—Methotrexate—urinary bladder cancer	0.000133	0.000708	CcSEcCtD
Propofol—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000132	0.000705	CcSEcCtD
Propofol—Syncope—Epirubicin—urinary bladder cancer	0.000131	0.000698	CcSEcCtD
Propofol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00013	0.000692	CcSEcCtD
Propofol—Confusional state—Methotrexate—urinary bladder cancer	0.000128	0.000684	CcSEcCtD
Propofol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000128	0.000684	CcSEcCtD
Propofol—Cough—Epirubicin—urinary bladder cancer	0.000127	0.000679	CcSEcCtD
Propofol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000127	0.000679	CcSEcCtD
Propofol—Convulsion—Epirubicin—urinary bladder cancer	0.000127	0.000674	CcSEcCtD
Propofol—Nausea—Etoposide—urinary bladder cancer	0.000126	0.000673	CcSEcCtD
Propofol—Hypertension—Epirubicin—urinary bladder cancer	0.000126	0.000672	CcSEcCtD
Propofol—Chest pain—Epirubicin—urinary bladder cancer	0.000124	0.000663	CcSEcCtD
Propofol—Myalgia—Epirubicin—urinary bladder cancer	0.000124	0.000663	CcSEcCtD
Propofol—Agitation—Doxorubicin—urinary bladder cancer	0.000124	0.000662	CcSEcCtD
Propofol—Anxiety—Epirubicin—urinary bladder cancer	0.000124	0.00066	CcSEcCtD
Propofol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000123	0.000656	CcSEcCtD
Propofol—Dry mouth—Epirubicin—urinary bladder cancer	0.000122	0.000648	CcSEcCtD
Propofol—Syncope—Doxorubicin—urinary bladder cancer	0.000121	0.000646	CcSEcCtD
Propofol—Confusional state—Epirubicin—urinary bladder cancer	0.00012	0.000641	CcSEcCtD
Propofol—Oedema—Epirubicin—urinary bladder cancer	0.000119	0.000635	CcSEcCtD
Propofol—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000119	0.000635	CcSEcCtD
Propofol—Hypotension—Methotrexate—urinary bladder cancer	0.000119	0.000634	CcSEcCtD
Propofol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000119	0.000633	CcSEcCtD
Propofol—Cough—Doxorubicin—urinary bladder cancer	0.000118	0.000628	CcSEcCtD
Propofol—Shock—Epirubicin—urinary bladder cancer	0.000117	0.000625	CcSEcCtD
Propofol—Convulsion—Doxorubicin—urinary bladder cancer	0.000117	0.000624	CcSEcCtD
Propofol—Hypertension—Doxorubicin—urinary bladder cancer	0.000117	0.000622	CcSEcCtD
Propofol—Tachycardia—Epirubicin—urinary bladder cancer	0.000116	0.00062	CcSEcCtD
Propofol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000116	0.000618	CcSEcCtD
Propofol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000115	0.000614	CcSEcCtD
Propofol—Insomnia—Methotrexate—urinary bladder cancer	0.000115	0.000614	CcSEcCtD
Propofol—Chest pain—Doxorubicin—urinary bladder cancer	0.000115	0.000613	CcSEcCtD
Propofol—Myalgia—Doxorubicin—urinary bladder cancer	0.000115	0.000613	CcSEcCtD
Propofol—Anxiety—Doxorubicin—urinary bladder cancer	0.000115	0.000611	CcSEcCtD
Propofol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000114	0.00061	CcSEcCtD
Propofol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000114	0.000605	CcSEcCtD
Propofol—Somnolence—Methotrexate—urinary bladder cancer	0.000113	0.000603	CcSEcCtD
Propofol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000112	0.0006	CcSEcCtD
Propofol—Hypotension—Epirubicin—urinary bladder cancer	0.000111	0.000594	CcSEcCtD
Propofol—Confusional state—Doxorubicin—urinary bladder cancer	0.000111	0.000593	CcSEcCtD
Propofol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00011	0.000588	CcSEcCtD
Propofol—Oedema—Doxorubicin—urinary bladder cancer	0.00011	0.000588	CcSEcCtD
Propofol—Fatigue—Methotrexate—urinary bladder cancer	0.00011	0.000585	CcSEcCtD
Propofol—Pain—Methotrexate—urinary bladder cancer	0.000109	0.00058	CcSEcCtD
Propofol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000109	0.000579	CcSEcCtD
Propofol—Shock—Doxorubicin—urinary bladder cancer	0.000108	0.000578	CcSEcCtD
Propofol—Insomnia—Epirubicin—urinary bladder cancer	0.000108	0.000575	CcSEcCtD
Propofol—Tachycardia—Doxorubicin—urinary bladder cancer	0.000108	0.000574	CcSEcCtD
Propofol—Paraesthesia—Epirubicin—urinary bladder cancer	0.000107	0.00057	CcSEcCtD
Propofol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000107	0.000568	CcSEcCtD
Propofol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000106	0.000566	CcSEcCtD
Propofol—Somnolence—Epirubicin—urinary bladder cancer	0.000106	0.000565	CcSEcCtD
Propofol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000105	0.000559	CcSEcCtD
Propofol—Hypotension—Doxorubicin—urinary bladder cancer	0.000103	0.000549	CcSEcCtD
Propofol—Fatigue—Epirubicin—urinary bladder cancer	0.000103	0.000548	CcSEcCtD
Propofol—Pain—Epirubicin—urinary bladder cancer	0.000102	0.000543	CcSEcCtD
Propofol—Urticaria—Methotrexate—urinary bladder cancer	0.000101	0.000539	CcSEcCtD
Propofol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000101	0.000537	CcSEcCtD
Propofol—Abdominal pain—Methotrexate—urinary bladder cancer	0.000101	0.000537	CcSEcCtD
Propofol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.0001	0.000536	CcSEcCtD
Propofol—Insomnia—Doxorubicin—urinary bladder cancer	9.97e-05	0.000532	CcSEcCtD
Propofol—Paraesthesia—Doxorubicin—urinary bladder cancer	9.9e-05	0.000528	CcSEcCtD
Propofol—Dyspnoea—Doxorubicin—urinary bladder cancer	9.83e-05	0.000524	CcSEcCtD
Propofol—Feeling abnormal—Epirubicin—urinary bladder cancer	9.82e-05	0.000523	CcSEcCtD
Propofol—Somnolence—Doxorubicin—urinary bladder cancer	9.8e-05	0.000523	CcSEcCtD
Propofol—Fatigue—Doxorubicin—urinary bladder cancer	9.51e-05	0.000507	CcSEcCtD
Propofol—Urticaria—Epirubicin—urinary bladder cancer	9.47e-05	0.000505	CcSEcCtD
Propofol—Pain—Doxorubicin—urinary bladder cancer	9.43e-05	0.000503	CcSEcCtD
Propofol—Abdominal pain—Epirubicin—urinary bladder cancer	9.42e-05	0.000502	CcSEcCtD
Propofol—Body temperature increased—Epirubicin—urinary bladder cancer	9.42e-05	0.000502	CcSEcCtD
Propofol—Asthenia—Methotrexate—urinary bladder cancer	9.14e-05	0.000487	CcSEcCtD
Propofol—Feeling abnormal—Doxorubicin—urinary bladder cancer	9.09e-05	0.000484	CcSEcCtD
Propofol—Pruritus—Methotrexate—urinary bladder cancer	9.01e-05	0.00048	CcSEcCtD
Propofol—Urticaria—Doxorubicin—urinary bladder cancer	8.76e-05	0.000467	CcSEcCtD
Propofol—Abdominal pain—Doxorubicin—urinary bladder cancer	8.72e-05	0.000465	CcSEcCtD
Propofol—Body temperature increased—Doxorubicin—urinary bladder cancer	8.72e-05	0.000465	CcSEcCtD
Propofol—Diarrhoea—Methotrexate—urinary bladder cancer	8.71e-05	0.000464	CcSEcCtD
Propofol—Asthenia—Epirubicin—urinary bladder cancer	8.55e-05	0.000456	CcSEcCtD
Propofol—Pruritus—Epirubicin—urinary bladder cancer	8.43e-05	0.000449	CcSEcCtD
Propofol—Dizziness—Methotrexate—urinary bladder cancer	8.42e-05	0.000449	CcSEcCtD
Propofol—Diarrhoea—Epirubicin—urinary bladder cancer	8.15e-05	0.000435	CcSEcCtD
Propofol—Vomiting—Methotrexate—urinary bladder cancer	8.1e-05	0.000432	CcSEcCtD
Propofol—Rash—Methotrexate—urinary bladder cancer	8.03e-05	0.000428	CcSEcCtD
Propofol—Dermatitis—Methotrexate—urinary bladder cancer	8.02e-05	0.000428	CcSEcCtD
Propofol—Headache—Methotrexate—urinary bladder cancer	7.98e-05	0.000425	CcSEcCtD
Propofol—Asthenia—Doxorubicin—urinary bladder cancer	7.91e-05	0.000422	CcSEcCtD
Propofol—Dizziness—Epirubicin—urinary bladder cancer	7.88e-05	0.00042	CcSEcCtD
Propofol—Pruritus—Doxorubicin—urinary bladder cancer	7.8e-05	0.000416	CcSEcCtD
Propofol—Vomiting—Epirubicin—urinary bladder cancer	7.58e-05	0.000404	CcSEcCtD
Propofol—Nausea—Methotrexate—urinary bladder cancer	7.56e-05	0.000403	CcSEcCtD
Propofol—Diarrhoea—Doxorubicin—urinary bladder cancer	7.54e-05	0.000402	CcSEcCtD
Propofol—Rash—Epirubicin—urinary bladder cancer	7.51e-05	0.000401	CcSEcCtD
Propofol—Dermatitis—Epirubicin—urinary bladder cancer	7.51e-05	0.0004	CcSEcCtD
Propofol—Headache—Epirubicin—urinary bladder cancer	7.47e-05	0.000398	CcSEcCtD
Propofol—Dizziness—Doxorubicin—urinary bladder cancer	7.29e-05	0.000389	CcSEcCtD
Propofol—Nausea—Epirubicin—urinary bladder cancer	7.08e-05	0.000377	CcSEcCtD
Propofol—Vomiting—Doxorubicin—urinary bladder cancer	7.01e-05	0.000374	CcSEcCtD
Propofol—Rash—Doxorubicin—urinary bladder cancer	6.95e-05	0.000371	CcSEcCtD
Propofol—Dermatitis—Doxorubicin—urinary bladder cancer	6.95e-05	0.00037	CcSEcCtD
Propofol—Headache—Doxorubicin—urinary bladder cancer	6.91e-05	0.000368	CcSEcCtD
Propofol—Nausea—Doxorubicin—urinary bladder cancer	6.55e-05	0.000349	CcSEcCtD
Propofol—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	1.33e-05	6.27e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—ENO2—urinary bladder cancer	1.33e-05	6.27e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.33e-05	6.23e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.32e-05	6.21e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.32e-05	6.2e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—RRM2—urinary bladder cancer	1.31e-05	6.17e-05	CbGpPWpGaD
Propofol—CYP2C18—Metabolism—PPARG—urinary bladder cancer	1.3e-05	6.11e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	1.29e-05	6.08e-05	CbGpPWpGaD
Propofol—CYP1B1—Metabolism—GPX1—urinary bladder cancer	1.28e-05	6.02e-05	CbGpPWpGaD
Propofol—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.27e-05	5.99e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.27e-05	5.98e-05	CbGpPWpGaD
Propofol—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	1.27e-05	5.96e-05	CbGpPWpGaD
Propofol—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	1.27e-05	5.96e-05	CbGpPWpGaD
Propofol—ALB—Hemostasis—IGF1—urinary bladder cancer	1.26e-05	5.92e-05	CbGpPWpGaD
Propofol—CYP1B1—Metabolism—ERCC2—urinary bladder cancer	1.26e-05	5.91e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.26e-05	5.9e-05	CbGpPWpGaD
Propofol—CYP2C18—Metabolism—CREBBP—urinary bladder cancer	1.25e-05	5.87e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.24e-05	5.85e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.23e-05	5.8e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.22e-05	5.74e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.22e-05	5.74e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—HPGDS—urinary bladder cancer	1.22e-05	5.71e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—ENO2—urinary bladder cancer	1.22e-05	5.71e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.22e-05	5.71e-05	CbGpPWpGaD
Propofol—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.21e-05	5.68e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	1.2e-05	5.65e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.19e-05	5.57e-05	CbGpPWpGaD
Propofol—CYP1B1—Metabolism—MTHFR—urinary bladder cancer	1.18e-05	5.56e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.18e-05	5.54e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—GSTT1—urinary bladder cancer	1.18e-05	5.54e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.18e-05	5.54e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.18e-05	5.53e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.17e-05	5.49e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.16e-05	5.47e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—NQO1—urinary bladder cancer	1.16e-05	5.47e-05	CbGpPWpGaD
Propofol—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.16e-05	5.46e-05	CbGpPWpGaD
Propofol—ALB—Hemostasis—RHOA—urinary bladder cancer	1.15e-05	5.42e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—NQO1—urinary bladder cancer	1.14e-05	5.36e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.13e-05	5.34e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.13e-05	5.31e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—TYMS—urinary bladder cancer	1.12e-05	5.26e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	1.11e-05	5.2e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	1.11e-05	5.2e-05	CbGpPWpGaD
Propofol—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.1e-05	5.19e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.09e-05	5.13e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.09e-05	5.13e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.08e-05	5.1e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.08e-05	5.09e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—NQO1—urinary bladder cancer	1.07e-05	5.05e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.07e-05	5.05e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.06e-05	5e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—GPX1—urinary bladder cancer	1.06e-05	4.98e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.06e-05	4.97e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.04e-05	4.9e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.04e-05	4.9e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	1.04e-05	4.89e-05	CbGpPWpGaD
Propofol—UGT1A1—Metabolism—PPARG—urinary bladder cancer	1.03e-05	4.83e-05	CbGpPWpGaD
Propofol—UGT1A9—Metabolism—PPARG—urinary bladder cancer	1.03e-05	4.83e-05	CbGpPWpGaD
Propofol—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	1.02e-05	4.81e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1e-05	4.72e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1e-05	4.72e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	9.95e-06	4.68e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—ENO2—urinary bladder cancer	9.95e-06	4.68e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.89e-06	4.65e-05	CbGpPWpGaD
Propofol—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	9.87e-06	4.64e-05	CbGpPWpGaD
Propofol—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	9.87e-06	4.64e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—NQO1—urinary bladder cancer	9.85e-06	4.63e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—NQO1—urinary bladder cancer	9.8e-06	4.6e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	9.77e-06	4.59e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	9.73e-06	4.57e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	9.71e-06	4.56e-05	CbGpPWpGaD
Propofol—ALB—Hemostasis—IL2—urinary bladder cancer	9.68e-06	4.55e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	9.65e-06	4.53e-05	CbGpPWpGaD
Propofol—CYP1B1—Metabolism—PPARG—urinary bladder cancer	9.58e-06	4.51e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.56e-06	4.49e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	9.51e-06	4.47e-05	CbGpPWpGaD
Propofol—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.5e-06	4.47e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.5e-06	4.47e-05	CbGpPWpGaD
Propofol—CYP1B1—Metabolism—CREBBP—urinary bladder cancer	9.21e-06	4.33e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—RRM2—urinary bladder cancer	9.18e-06	4.31e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.09e-06	4.27e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—TYMP—urinary bladder cancer	9.07e-06	4.27e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—TYMS—urinary bladder cancer	9.02e-06	4.24e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	8.96e-06	4.21e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	8.92e-06	4.19e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	8.92e-06	4.19e-05	CbGpPWpGaD
Propofol—CYP2C18—Metabolism—PTEN—urinary bladder cancer	8.92e-06	4.19e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—TYMS—urinary bladder cancer	8.84e-06	4.15e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—NQO1—urinary bladder cancer	8.79e-06	4.13e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	8.74e-06	4.11e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	8.74e-06	4.11e-05	CbGpPWpGaD
Propofol—ALB—Hemostasis—EP300—urinary bladder cancer	8.68e-06	4.08e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.67e-06	4.08e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—GPX1—urinary bladder cancer	8.54e-06	4.01e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.53e-06	4.01e-05	CbGpPWpGaD
Propofol—CYP2C18—Metabolism—EP300—urinary bladder cancer	8.51e-06	4e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—ENO2—urinary bladder cancer	8.5e-06	4e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	8.5e-06	4e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.45e-06	3.97e-05	CbGpPWpGaD
Propofol—ALB—Hemostasis—SRC—urinary bladder cancer	8.44e-06	3.97e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	8.39e-06	3.94e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—GPX1—urinary bladder cancer	8.37e-06	3.93e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.34e-06	3.92e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—TYMS—urinary bladder cancer	8.33e-06	3.92e-05	CbGpPWpGaD
Propofol—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.29e-06	3.9e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	8.24e-06	3.88e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	8.24e-06	3.87e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	8.24e-06	3.87e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	8.22e-06	3.86e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	8.21e-06	3.86e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.21e-06	3.86e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—GSTP1—urinary bladder cancer	8.17e-06	3.84e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.12e-06	3.82e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—NQO1—urinary bladder cancer	8.09e-06	3.8e-05	CbGpPWpGaD
Propofol—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	8.08e-06	3.8e-05	CbGpPWpGaD
Propofol—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	8.08e-06	3.8e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—NQO1—urinary bladder cancer	8.02e-06	3.77e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.95e-06	3.74e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—PPARG—urinary bladder cancer	7.92e-06	3.72e-05	CbGpPWpGaD
Propofol—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.9e-06	3.72e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—GPX1—urinary bladder cancer	7.89e-06	3.71e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	7.88e-06	3.7e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.78e-06	3.66e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	7.74e-06	3.64e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	7.72e-06	3.63e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—TYMS—urinary bladder cancer	7.64e-06	3.59e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	7.61e-06	3.58e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—TYMS—urinary bladder cancer	7.59e-06	3.57e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	7.55e-06	3.55e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	7.55e-06	3.55e-05	CbGpPWpGaD
Propofol—CYP1B1—Metabolism—PTGS2—urinary bladder cancer	7.54e-06	3.54e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—NCOR1—urinary bladder cancer	7.51e-06	3.53e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—GSTM1—urinary bladder cancer	7.51e-06	3.53e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.44e-06	3.5e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	7.33e-06	3.45e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	7.28e-06	3.42e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—GPX1—urinary bladder cancer	7.23e-06	3.4e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—GPX1—urinary bladder cancer	7.19e-06	3.38e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	7.1e-06	3.34e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.1e-06	3.34e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—RRM2—urinary bladder cancer	7.08e-06	3.33e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—ERCC2—urinary bladder cancer	7.06e-06	3.32e-05	CbGpPWpGaD
Propofol—UGT1A1—Metabolism—PTEN—urinary bladder cancer	7.05e-06	3.31e-05	CbGpPWpGaD
Propofol—UGT1A9—Metabolism—PTEN—urinary bladder cancer	7.05e-06	3.31e-05	CbGpPWpGaD
Propofol—ALB—Hemostasis—KRAS—urinary bladder cancer	6.99e-06	3.29e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—NQO1—urinary bladder cancer	6.85e-06	3.22e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—TYMS—urinary bladder cancer	6.82e-06	3.2e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.78e-06	3.19e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.75e-06	3.17e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	6.74e-06	3.17e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	6.74e-06	3.17e-05	CbGpPWpGaD
Propofol—UGT1A1—Metabolism—EP300—urinary bladder cancer	6.72e-06	3.16e-05	CbGpPWpGaD
Propofol—UGT1A9—Metabolism—EP300—urinary bladder cancer	6.72e-06	3.16e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	6.69e-06	3.14e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	6.67e-06	3.14e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.65e-06	3.12e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—MTHFR—urinary bladder cancer	6.63e-06	3.12e-05	CbGpPWpGaD
Propofol—CYP1B1—Metabolism—PTEN—urinary bladder cancer	6.57e-06	3.09e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.56e-06	3.08e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.56e-06	3.08e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.47e-06	3.04e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—GPX1—urinary bladder cancer	6.45e-06	3.03e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—PPARG—urinary bladder cancer	6.39e-06	3e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.36e-06	2.99e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	6.34e-06	2.98e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.27e-06	2.95e-05	CbGpPWpGaD
Propofol—CYP1B1—Metabolism—EP300—urinary bladder cancer	6.27e-06	2.95e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—PPARG—urinary bladder cancer	6.26e-06	2.94e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	6.23e-06	2.93e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—TYMS—urinary bladder cancer	6.22e-06	2.92e-05	CbGpPWpGaD
Propofol—ALB—Hemostasis—TP53—urinary bladder cancer	6.21e-06	2.92e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	6.2e-06	2.91e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	6.2e-06	2.91e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	6.15e-06	2.89e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	6.15e-06	2.89e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	6.14e-06	2.89e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	6.01e-06	2.83e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	5.96e-06	2.8e-05	CbGpPWpGaD
Propofol—ALB—Hemostasis—HRAS—urinary bladder cancer	5.94e-06	2.79e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.94e-06	2.79e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—PPARG—urinary bladder cancer	5.9e-06	2.77e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.88e-06	2.77e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.83e-06	2.74e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.8e-06	2.73e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	5.78e-06	2.72e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	5.71e-06	2.69e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	5.67e-06	2.67e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.53e-06	2.6e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.48e-06	2.58e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—PTEN—urinary bladder cancer	5.43e-06	2.55e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.43e-06	2.55e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—PPARG—urinary bladder cancer	5.41e-06	2.54e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—PPARG—urinary bladder cancer	5.38e-06	2.53e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—TYMS—urinary bladder cancer	5.31e-06	2.5e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.29e-06	2.49e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	5.25e-06	2.47e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	5.25e-06	2.47e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	5.2e-06	2.44e-05	CbGpPWpGaD
Propofol—CYP2A6—Metabolism—EP300—urinary bladder cancer	5.18e-06	2.44e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—CREBBP—urinary bladder cancer	5.17e-06	2.43e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—GPX1—urinary bladder cancer	5.03e-06	2.36e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	5.03e-06	2.36e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	4.94e-06	2.32e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	4.92e-06	2.31e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—PPARG—urinary bladder cancer	4.83e-06	2.27e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	4.64e-06	2.18e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	4.64e-06	2.18e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	4.64e-06	2.18e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.44e-06	2.09e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.41e-06	2.07e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.4e-06	2.07e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—PTEN—urinary bladder cancer	4.38e-06	2.06e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—PTEN—urinary bladder cancer	4.29e-06	2.02e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.27e-06	2.01e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	4.26e-06	2e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—PTGS2—urinary bladder cancer	4.23e-06	1.99e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	4.23e-06	1.99e-05	CbGpPWpGaD
Propofol—CYP2B6—Metabolism—EP300—urinary bladder cancer	4.18e-06	1.97e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.1e-06	1.93e-05	CbGpPWpGaD
Propofol—CYP2E1—Metabolism—EP300—urinary bladder cancer	4.1e-06	1.93e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.05e-06	1.91e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.05e-06	1.91e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—PTEN—urinary bladder cancer	4.05e-06	1.9e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.88e-06	1.82e-05	CbGpPWpGaD
Propofol—CYP1A1—Metabolism—EP300—urinary bladder cancer	3.86e-06	1.82e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.81e-06	1.79e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	3.8e-06	1.79e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—PPARG—urinary bladder cancer	3.76e-06	1.77e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—PTEN—urinary bladder cancer	3.71e-06	1.74e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—PTEN—urinary bladder cancer	3.69e-06	1.74e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	3.62e-06	1.7e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.58e-06	1.68e-05	CbGpPWpGaD
Propofol—CYP2C8—Metabolism—EP300—urinary bladder cancer	3.54e-06	1.66e-05	CbGpPWpGaD
Propofol—ALB—Metabolism—EP300—urinary bladder cancer	3.52e-06	1.65e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.49e-06	1.64e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.46e-06	1.63e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—PTEN—urinary bladder cancer	3.31e-06	1.56e-05	CbGpPWpGaD
Propofol—CYP2C19—Metabolism—EP300—urinary bladder cancer	3.16e-06	1.49e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—PTEN—urinary bladder cancer	3.05e-06	1.43e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3.02e-06	1.42e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	2.96e-06	1.39e-05	CbGpPWpGaD
Propofol—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.91e-06	1.37e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.9e-06	1.37e-05	CbGpPWpGaD
Propofol—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.88e-06	1.35e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.79e-06	1.31e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—PTEN—urinary bladder cancer	2.58e-06	1.21e-05	CbGpPWpGaD
Propofol—CYP1A2—Metabolism—EP300—urinary bladder cancer	2.46e-06	1.16e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.28e-06	1.07e-05	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.99e-06	9.37e-06	CbGpPWpGaD
Propofol—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.9e-06	8.93e-06	CbGpPWpGaD
